{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:54:51Z","timestamp":1792007691024,"version":"4.4.0"},"reference-count":101,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.1248\/bpb.b25-00787","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:12:26Z","timestamp":1777587146000},"page":"759-769","source":"Crossref","is-referenced-by-count":3,"title":["The Dual Role of Saikosaponins in Liver Disease Treatment: A Comprehensive Review of Pharmacological Activities and Toxicological Characteristics"],"prefix":"10.1248","volume":"49","author":[{"given":"Shanfei","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingying","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Panyu Hospital of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benliang","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinggang","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Trauma Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wang J, Wang H, Yang X, Wang K, Zhang Y. Recent advances in the role of polysaccharides in liver diseases: a review. Front. Pharmacol.<\/i>, 16<\/b>, 1535717 (2025).","DOI":"10.3389\/fphar.2025.1535717"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, Jepsen P, Golfieri R, Galle P, Dawson L, Reig M. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J. Hepatol.<\/i>, 82<\/b>, 315\u2013374 (2025).","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yeo YH, Abdelmalek M, Khan S, Moylan CA, Rodriquez L, Villanueva A, Yang JD. Current and emerging strategies for the prevention of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol.<\/i>, 22<\/b>, 173\u2013190 (2025).","DOI":"10.1038\/s41575-024-01021-z"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol.<\/i>, 20<\/b>, 864\u2013884 (2023).","DOI":"10.1038\/s41571-023-00825-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sun Y, Pan H, Shen S, Xia Z, Yu Z, Li C, Sun P, Xin C. Alisma shugan decoction (ASD) ameliorates hepatotoxicity and associated liver dysfunction by inhibiting oxidative stress and p65\/Nrf2\/JunD signaling dysregulation in vivo.<\/i> Med. Sci. Monit.<\/i>, 26<\/b>, e921738 (2020).","DOI":"10.12659\/MSM.921738"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Qi X, Bai Z, Zhu Q, et al.<\/i> Practice guidance for the use of terlipressin for liver cirrhosis-related complications. Ther. Adv. Gastroenterol.<\/i>, 15<\/b>, 17562848221098253 (2022).","DOI":"10.1177\/17562848221098253"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut<\/i>, 69<\/b>, 953\u2013962 (2020).","DOI":"10.1136\/gutjnl-2019-318237"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Singal AG, Salem R, Pinato DJ, Pillai A. Advances in locoregional and systemic treatments for hepatocellular carcinoma. Gastroenterology<\/i>, 169<\/b>, 585\u2013599 (2025).","DOI":"10.1053\/j.gastro.2025.03.047"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Zhu Y, Lai Y. Pharmacological properties and derivatives of saikosaponins\u2014a review of recent studies. J. Pharm. Pharmacol.<\/i>, 75<\/b>, 898\u2013909 (2023).","DOI":"10.1093\/jpp\/rgad052"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sun T, Luo J, Xu Y, Sun X, Yang S, Yang M. Ultra-high performance supercritical fluid chromatography method for separation and quantitation of saikosaponins in herbal medicine. J. Pharm. Biomed. Anal.<\/i>, 199<\/b>, 114039 (2021).","DOI":"10.1016\/j.jpba.2021.114039"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhou Q, Wu W-W, Yu C-L, Wang P, Wen X-Q, Chen B-L, Zhang Y, Zhuang M, Zhang M-Y, Zhang H-Y, Zhang J-W. Saikosaponin A inhibits growth of human bladder carcinoma T24 and 5637 cells both in vitro<\/i> and in vivo.<\/i> Biol. Pharm. Bull.<\/i>, 45<\/b>, 863\u2013871 (2022).","DOI":"10.1248\/bpb.b21-01025"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Li X, Li X, Huang N, Liu R, Sun R. A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins. Phytomedicine<\/i>, 50<\/b>, 73\u201387 (2018).","DOI":"10.1016\/j.phymed.2018.09.174"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gu S, Zheng Y, Chen C, Liu J, Wang Y, Wang J, Li Y. Research progress on the molecular mechanisms of Saikosaponin D in various diseases (review). Int. J. Mol. Med.<\/i>, 55<\/b>, 37 (2025).","DOI":"10.3892\/ijmm.2024.5478"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Zhu Y, Chen X, Rao X, Zheng C, Peng X. Saikosaponin a ameliorates lipopolysaccharide and D-galactosamine-induced liver injury via<\/i> activating LXR\u03b1. Int. Immunopharmacol.<\/i>, 72<\/b>, 131\u2013137 (2019).","DOI":"10.1016\/j.intimp.2019.03.049"},{"key":"15","unstructured":"15) Zhu S, Zhang J, Hao D, Yuan W, Wu F, Wang B. Saikosaponin D attenuates hepatic ischemia-reperfusion injury by inhibiting inflammatory response in rats. Chin. J. Exp. Surg.<\/i>, 41<\/b>, 2006\u20132010 (2024)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Chen MF, Huang SJ, Huang CC, Liu PS, Lin KI, Liu CW, Hsieh WC, Shiu LY, Chen CH. Saikosaponin d induces cell death through caspase-3-dependent, caspase-3-independent and mitochondrial pathways in mammalian hepatic stellate cells. BMC Cancer<\/i>, 16<\/b>, 532 (2016).","DOI":"10.1186\/s12885-016-2599-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Zhang K, Lin L, Zhu Y, Zhang N, Zhou M, Li Y. Saikosaponin d alleviates liver fibrosis by negatively regulating the ROS\/NLRP3 inflammasome through activating the ER\u03b2 pathway. Front. Pharmacol.<\/i>, 13<\/b>, 894981 (2022).","DOI":"10.3389\/fphar.2022.894981"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zheng Q, Li X, Huang N, Li F, Ge J, Wang D, Sun R, Liu R. Saikosaponins ameliorate hyperlipidemia in rats by enhancing hepatic lipid and cholesterol metabolism. J. Ethnopharmacol.<\/i>, 305<\/b>, 116110 (2023).","DOI":"10.1016\/j.jep.2022.116110"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Lee J-K, Kim J-H, Shin HK. Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma. Hepatol. Res.<\/i>, 41<\/b>, 825\u2013837 (2011).","DOI":"10.1111\/j.1872-034X.2011.00829.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Teschke R, Wolff A, Frenzel C, Schulze J. Review article: Herbal hepatotoxicity\u2014an update on traditional Chinese medicine preparations. Aliment. Pharmacol. Ther.<\/i>, 40<\/b>, 32\u201350 (2014).","DOI":"10.1111\/apt.12798"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Shaker ME. The contribution of sterile inflammation to the fatty liver disease and the potential therapies. Biomed. Pharmacother.<\/i>, 148<\/b>, 112789 (2022).","DOI":"10.1016\/j.biopha.2022.112789"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Liu A, Tanaka N, Sun L, Guo B, Kim JH, Krausz KW, Fang Z, Jiang C, Yang J, Gonzalez FJ. Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-\u03baB and STAT3 signaling. Chem. Biol. Interact.<\/i>, 223<\/b>, 80\u201386 (2014).","DOI":"10.1016\/j.cbi.2014.09.012"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lin L, Que R, Shen Y, Chen Y, Yan N, Li Y. Saikosaponin-d alleviates carbon-tetrachloride induced acute hepatocellular injury by inhibiting oxidative stress and NLRP3 inflammasome activation in the HL-7702 cell line. Mol. Med. Rep.<\/i>, 17<\/b>, 7939\u20137946 (2018).","DOI":"10.3892\/mmr.2018.8849"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Wei Z, Wang J, Shi M, Liu W, Yang Z, Fu Y. Saikosaponin a inhibits LPS-induced inflammatory response by inducing liver X receptor alpha activation in primary mouse macrophages. Oncotarget<\/i>, 7<\/b>, 48995\u201349007 (2016).","DOI":"10.18632\/oncotarget.9863"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ma Y, Bao Y, Wang S, Li T, Chang X, Yang G, Meng X. Anti-inflammation effects and potential mechanism of saikosaponins by regulating nicotinate and nicotinamide metabolism and arachidonic acid metabolism. Inflammation<\/i>, 39<\/b>, 1453\u20131461 (2016).","DOI":"10.1007\/s10753-016-0377-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lee W-P, Lan K-L, Liao S-X, Huang Y-H, Hou M-C, Lan K-H. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. J. Chin. Med. Assoc.<\/i>, 82<\/b>, 368\u2013374 (2019).","DOI":"10.1097\/JCMA.0000000000000095"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Jim\u00e9nez-Uribe AP, G\u00f3mez-Sierra T, Aparicio-Trejo OE, Orozco-Ibarra M, Pedraza-Chaverri J. Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-\u03b2. Cell. Signal.<\/i>, 87<\/b>, 110123 (2021).","DOI":"10.1016\/j.cellsig.2021.110123"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Yan Y, Zeng J, Xing L, Li C. Extra- and intra-cellular mechanisms of hepatic stellate cell activation. Biomedicines<\/i>, 9<\/b>, 1014 (2021).","DOI":"10.3390\/biomedicines9081014"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Zou X, Ke Y, Shao Y, Liu S, Shi T. Liver fibrosis: interactions between cells and microenvironments. Turk. J. Gastroenterol.<\/i>, 36<\/b>, 711\u2013722 (2025).","DOI":"10.5152\/tjg.2025.25313"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Li S, Wang R, Song F, Chen P, Gu Y, Chen C, Yuan Y. Salvianolic acid A suppresses CCl4-induced liver fibrosis through regulating the Nrf2\/HO-1, NF-\u03baB\/I\u03baB\u03b1, p38 MAPK, and JAK1\/STAT3 signaling pathways. Drug Chem. Toxicol.<\/i>, 46<\/b>, 304\u2013313 (2022).","DOI":"10.1080\/01480545.2022.2028822"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem. Biol. Interact.<\/i>, 193<\/b>, 225\u2013231 (2011).","DOI":"10.1016\/j.cbi.2011.07.001"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ramos-Tovar E, Muriel P. Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver. Antioxidants<\/i>, 9<\/b>, 1279 (2020).","DOI":"10.3390\/antiox9121279"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Jiang H, Liu J, Zhang K, Zeng Q. Saikosaponin D inhibits the proliferation and promotes the apoptosis of rat hepatic stellate cells by inducing autophagosome formation. Evid. Based Complement. Alternat. Med.<\/i>, 2021<\/b>, 5451758 (2021).","DOI":"10.1155\/2021\/5451758"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Que R, Shen Y, Ren J, Tao Z, Zhu X, Li Y. Estrogen receptor-\u03b2-dependent effects of saikosaponin-d on the suppression of oxidative stress-induced rat hepatic stellate cell activation. Int. J. Mol. Med.<\/i>, 41<\/b>, 1357\u20131364 (2018).","DOI":"10.3892\/ijmm.2017.3349"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Chen Y, Que R, Zhang N, Lin L, Zhou M, Li Y. Saikosaponin-d alleviates hepatic fibrosis through regulating GPER1\/autophagy signaling. Mol. Biol. Rep.<\/i>, 48<\/b>, 7853\u20137863 (2021).","DOI":"10.1007\/s11033-021-06807-x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Shiu L-Y, Huang HH, Chen CY, Cheng H-Y, Chen CI, Kuo SM. Reparative and toxicity-reducing effects of liposome-encapsulated saikosaponin in mice with liver fibrosis. Biosci. Rep.<\/i>, 40<\/b>, BSR20201219 (2020).","DOI":"10.1042\/BSR20201219"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Chen MF, Huang CC, Liu PS, Chen CH, Shiu LY. Saikosaponin a and saikosaponin d inhibit proliferation and migratory activity of rat HSC-T6 cells. J. Med. Food<\/i>, 16<\/b>, 793\u2013800 (2013).","DOI":"10.1089\/jmf.2013.2762"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Li C, Huang L, Sun W, Chen Y, He M-L, Yue J, Ballard H. Saikosaponin D suppresses enterovirus A71 infection by inhibiting autophagy. Signal Transduct. Target. Ther.<\/i>, 4<\/b>, 4 (2019).","DOI":"10.1038\/s41392-019-0037-x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Chen C-H, Chen M-F, Huang SJ, Huang C-Y, Wang H-K, Hsieh W-C, Huang C-H, Liu L-F, Shiu L-Y. Saikosaponin a induces apoptosis through mitochondria-dependent pathway in hepatic stellate cells. Am. J. Chin. Med.<\/i>, 45<\/b>, 351\u2013368 (2017).","DOI":"10.1142\/S0192415X17500227"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Wang X, Wang Q, Burczynski FJ, Kong W, Gong Y. Saikosaponin A of Bupleurum chinense<\/i> (Chaihu) elevates bone morphogenetic protein 4 (BMP-4) during hepatic stellate cell activation. Phytomedicine<\/i>, 20<\/b>, 1330\u20131335 (2013).","DOI":"10.1016\/j.phymed.2013.07.010"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Sugimoto A, Saito Y, Wang G, et al.<\/i> Hepatic stellate cells control liver zonation, size and functions via<\/i> R-spondin 3. Nature<\/i>, 640<\/b>, 752\u2013761 (2025).","DOI":"10.1038\/s41586-025-08677-w"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat. Rev. Dis. Primers<\/i>, 7<\/b>, 6 (2021).","DOI":"10.1038\/s41572-020-00240-3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Chen H, Cai W, Chu ESH, Tang J, Wong C-C, Wong SH, Sun W, Liang Q, Fang J, Sun Z, Yu J. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene<\/i>, 36<\/b>, 4415\u20134426 (2017).","DOI":"10.1038\/onc.2017.73"},{"key":"44","unstructured":"44) Lu X-L, He S-X, Ren M-D, Wang Y-L, Zhang Y-X, Liu E-Q. Chemopreventive effect of saikosaponin-d on diethylinitrosamine-induced hepatocarcinogenesis: involvement of CCAAT\/enhancer binding protein \u03b2 and cyclooxygenase-2. Mol. Med. Rep.<\/i>, 5<\/b>, 637\u2013644 (2012)."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Ren M, McGowan E, Li Y, Zhu X, Lu X, Zhu Z, Lin Y, He S. Saikosaponin-d suppresses COX2 through p-STAT3\/C\/EBP\u03b2 signaling pathway in liver cancer: a novel mechanism of action. Front. Pharmacol.<\/i>, 10<\/b>, 623 (2019).","DOI":"10.3389\/fphar.2019.00623"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) He S, Lu G, Hou H, Zhao Z, Zhu Z, Lu X, Chen J, Wang Z. Saikosaponin-d suppresses the expression of cyclooxygenase-2 through the phospho-signal transducer and activator of transcription 3\/hypoxia-inducible factor-1\u03b1 pathway in hepatocellular carcinoma cells. Mol. Med. Rep.<\/i>, 10<\/b>, 2556\u20132562 (2014).","DOI":"10.3892\/mmr.2014.2574"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Hsu Y-L, Kuo P-L, Chiang L-C, Lin C-C. Involvement of p53, nuclear factor \u03baB and fas\/fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett.<\/i>, 213<\/b>, 213\u2013221 (2004).","DOI":"10.1016\/j.canlet.2004.03.044"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) You M, Fu J, Lv X, Wang L, Wang H, Li R. Saikosaponin b2 inhibits tumor angiogenesis in liver cancer via<\/i> down-regulation of VEGF\/ERK\/HIF-1\u03b1 signaling. Oncol. Rep.<\/i>, 50<\/b>, 136 (2023).","DOI":"10.3892\/or.2023.8573"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Lan T, Wang W, Zeng X-X, Tong Y-H, Mao Z-J, Wang S-W. Saikosaponin a triggers cell ferroptosis in hepatocellular carcinoma by inducing endoplasmic reticulum stress-stimulated ATF3 expression. Biochem. Biophys. Res. Commun.<\/i>, 674<\/b>, 10\u201318 (2023).","DOI":"10.1016\/j.bbrc.2023.06.086"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Tian Y-D, Lin S, Yang P-T, Bai M-H, Jin Y-Y, Min W-L, Ma H-B, Wang B-F. Saikosaponin-d Increases the radiosensitivity of hepatoma cells by adjusting cell autophagy. J. Cancer<\/i>, 10<\/b>, 4947\u20134953 (2019).","DOI":"10.7150\/jca.30286"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Wang B-F, Dai Z-J, Wang X-J, Bai M-H, Lin S, Ma H-B, Wang Y-L, Song L-Q, Ma X-L, Zan Y, Min W-L, Cheng Y-A. Saikosaponin-d increases the radiosensitivity of smmc-7721 hepatocellular carcinoma cells by adjusting the g0\/g1 and g2\/m checkpoints of the cell cycle. BMC Complement. Altern. Med.<\/i>, 13<\/b>, 263 (2013).","DOI":"10.1186\/1472-6882-13-263"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Wang B-F, Wang X-J, Kang H-F, Bai M-H, Guan H-T, Wang Z-W, Zan Y, Song L-Q, Min W-L, Lin S, Cheng Y-A. Saikosaponin-D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1\u03b1. Cell. Physiol. Biochem.<\/i>, 33<\/b>, 37\u201351 (2014).","DOI":"10.1159\/000356648"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Wang B, Min W, Lin S, Song L, Yang P, Ma Q, Guo J. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via<\/i> inhibiting mTOR phosphorylation. Int. J. Med. Sci.<\/i>, 18<\/b>, 1465\u20131473 (2021).","DOI":"10.7150\/ijms.53024"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Zhang C-Y, Jiang Z-M, Ma X-F, Li Y, Liu X-Z, Li L-L, Wu W-H, Wang T. Saikosaponin-d inhibits the hepatoma cells and enhances chemosensitivity through SENP5-dependent inhibition of Gli1 SUMOylation under hypoxia. Front. Pharmacol.<\/i>, 10<\/b>, 1039 (2019).","DOI":"10.3389\/fphar.2019.01039"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Song F, Wang C-G, Wang T-L, Tao Y-C, Mao J-Z, Hu C-W, Zhang Y, Tang P-J, Lu C-L, Qing H-L, Han L, Chen Z. Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through saikosaponin-a mediated modulation of the p-AKT\/BCL-6\/ABCA1 axis. Phytomedicine<\/i>, 133<\/b>, 155944 (2024).","DOI":"10.1016\/j.phymed.2024.155944"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Zhao Y, Feng L, Liu L, Zhao R. Saikosaponin b2 enhances the hepatotargeting effect of anticancer drugs through inhibition of multidrug resistance-associated drug transporters. Life Sci.<\/i>, 231<\/b>, 116557 (2019).","DOI":"10.1016\/j.lfs.2019.116557"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Zhou P, Shi W, He XY, Du QY, Wang F, Guo J. Saikosaponin D: review on the antitumour effects, toxicity and pharmacokinetics. Pharm. Biol.<\/i>, 59<\/b>, 1478\u20131489 (2021).","DOI":"10.1080\/13880209.2021.1992448"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Baek J, Lee M-G. Oxidative stress and antioxidant strategies in dermatology. Redox Rep.<\/i>, 21<\/b>, 164\u2013169 (2016).","DOI":"10.1179\/1351000215Y.0000000015"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Naraki K, Rezaee R, Karimi G. A review on the protective effects of naringenin against natural and chemical toxic agents. Phytother. Res.<\/i>, 35<\/b>, 4075\u20134091 (2021).","DOI":"10.1002\/ptr.7071"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Jali AM, Alam MF, Hanbashi A, Mawkili W, Abdlasaed BM, Alshahrani S, Qahl AM, Alrashah ASS, Shahi HA. Sesamin\u2019s therapeutic actions on cyclophosphamide-induced hepatotoxicity, molecular mechanisms, and histopathological characteristics. Biomedicines<\/i>, 11<\/b>, 3238 (2023).","DOI":"10.3390\/biomedicines11123238"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Chen Y, Que R, Lin L, Shen Y, Liu J, Li Y. Inhibition of oxidative stress and NLRP3 inflammasome by Saikosaponin-d alleviates acute liver injury in carbon tetrachloride-induced hepatitis in mice. Int. J. Immunopathol. Pharmacol.<\/i>, 34<\/b>, 2058738420950593 (2020).","DOI":"10.1177\/2058738420950593"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Wang T-Y, Wang R-F, Bu Z-Y, Targher G, Byrne CD, Sun D-Q, Zheng M-H. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat. Rev. Nephrol.<\/i>, 18<\/b>, 259\u2013268 (2022).","DOI":"10.1038\/s41581-021-00519-y"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol.<\/i>, 15<\/b>, 11\u201320 (2018).","DOI":"10.1038\/nrgastro.2017.109"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Gu Y, Duan S, Ding M, Zheng Q, Fan G, Li X, Li Y, Liu C, Sun R, Liu R. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPAR\u03b1 and INSIG\/SREBP1c pathway. Phytomedicine<\/i>, 103<\/b>, 154219 (2022).","DOI":"10.1016\/j.phymed.2022.154219"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Lin L-T, Chung C-Y, Hsu W-C, Chang S-P, Hung T-C, Shields J, Russell RS, Lin C-C, Li C-F, Yen M-H, Tyrrell DLJ, Lin C-C, Richardson CD. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J. Hepatol.<\/i>, 62<\/b>, 541\u2013548 (2015).","DOI":"10.1016\/j.jhep.2014.10.040"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Chiang L-C, Ng LT, Liu L-T, Shieh D-E, Lin C-C. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from bupleurum species. Planta Med.<\/i>, 69<\/b>, 705\u2013709 (2003).","DOI":"10.1055\/s-2003-42797"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Wu S-J, Tam K-W, Tsai Y-H, Chang C-C, Chao JC-J. Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats. Am. J. Chin. Med.<\/i>, 38<\/b>, 99\u2013111 (2010).","DOI":"10.1142\/S0192415X10007695"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Jia X, Dang S, Cheng Y, Zhang X, Li M, Li Y, Li S. Effects of saikosaponin-d on syndecan-2, matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 in rats with hepatocellular carcinoma. J. Tradit. Chin. Med.<\/i>, 32<\/b>, 415\u2013422 (2012).","DOI":"10.1016\/S0254-6272(13)60048-5"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Wong VKW, Zhang MM, Zhou H, Lam KYC, Chan PL, Law CKM, Yue PYK, Liu L. Saikosaponin-d enhances the anticancer potency of TNF-\u03b1 via<\/i> overcoming its undesirable response of activating NF-kappa B signalling in cancer cells. Evid. Based Complement. Alternat. Med.<\/i>, 2013<\/b>, 745295 (2013).","DOI":"10.1155\/2013\/745295"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Wang B-F, Lin S, Bai MH, Song L-Q, Min W-L, Wang M, Yang P, Ma H-B, Wang X-J. Effects of SSd combined with radiation on inhibiting SMMC-7721 hepatoma cell growth. Med. Sci. Monit.<\/i>, 20<\/b>, 1340\u20131344 (2014).","DOI":"10.12659\/MSM.891355"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Wu WS, Hsu HY. Involvement of p-15(INK4b) and p-16(INK4a) gene expression in saikosaponin a and TPA-induced growth inhibition of HepG2 cells. Biochem. Biophys. Res. Commun.<\/i>, 285<\/b>, 183\u2013187 (2001).","DOI":"10.1006\/bbrc.2001.5152"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Ye R-P, Chen Z-D. Saikosaponin A, an active glycoside from Radix bupleuri<\/i>, reverses P-glycoprotein-mediated multidrug resistance in MCF-7\/ADR cells and HepG2\/ADM cells. Xenobiotica<\/i>, 47<\/b>, 176\u2013184 (2017).","DOI":"10.3109\/00498254.2016.1171932"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Li X, Li X, Lu J, Huang Y, Lv L, Luan Y, Liu R, Sun R. Saikosaponins induced hepatotoxicity in mice via<\/i> lipid metabolism dysregulation and oxidative stress: a proteomic study. BMC Complement. Altern. Med.<\/i>, 17<\/b>, 219 (2017).","DOI":"10.1186\/s12906-017-1733-0"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Li H, Tang Y, Wei W, Yin C, Tang F. Effects of saikosaponin-d on CYP3A4 in HepaRG cell and protein-ligand docking study. Basic Clin. Pharmacol. Toxicol.<\/i>, 128<\/b>, 661\u2013668 (2021).","DOI":"10.1111\/bcpt.13552"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Chen L, Zhang F, Kong D, Zhu X, Chen W, Wang A, Zheng S. Saikosaponin D disrupts platelet-derived growth factor-\u03b2 receptor\/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem. Biol. Interact.<\/i>, 206<\/b>, 76\u201382 (2013).","DOI":"10.1016\/j.cbi.2013.08.006"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Zhang F, Chen L, Jin H, Shao J, Wu L, Lu Y, Zheng S. Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity. Environ. Toxicol. Pharmacol.<\/i>, 41<\/b>, 8\u201313 (2016).","DOI":"10.1016\/j.etap.2015.11.005"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Zhang QQ, Huang WQ, Gao YQ, Han ZD, Zhang W, Zhang ZJ, Xu FG. Metabolomics reveals the efficacy of caspase inhibition for Saikosaponin D-induced hepatotoxicity. Front. Pharmacol.<\/i>, 9<\/b>, 732 (2018).","DOI":"10.3389\/fphar.2018.00732"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Wang Y-F, Ma R-X, Zou B, Li J, Yao Y, Li J. Endoplasmic reticulum stress regulates autophagic response that is involved in Saikosaponin a-induced liver cell damage. Toxicol. In Vitro<\/i>, 88<\/b>, 105534 (2023).","DOI":"10.1016\/j.tiv.2022.105534"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Fan G, Li X, Li F, Chen R, Xue X, Wang L, Zheng Q, Duan S, Luo R, Sun R, Liu R. Saikosaponin D exacerbates acetaminophen-induced liver injury by sabotaging GABARAP-SNARE complex assembly in protective autophagy. Phytomedicine<\/i>, 138<\/b>, 156409 (2025).","DOI":"10.1016\/j.phymed.2025.156409"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol. Sci.<\/i>, 65<\/b>, 166\u2013176 (2002).","DOI":"10.1093\/toxsci\/65.2.166"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Yu X, Pan J, Shen N, Zhang H, Zou L, Miao H, Xing L. Development of Saikosaponin D Liposome Nanocarrier with Increased Hepatoprotective Effect Against Alcoholic Hepatitis Mice. J. Biomed. Nanotechnol.<\/i>, 17<\/b>, 627\u2013639 (2021).","DOI":"10.1166\/jbn.2021.3054"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQH, Portincasa P. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J. Gastroenterol.<\/i>, 15<\/b>, 4865\u20134876 (2009).","DOI":"10.3748\/wjg.15.4865"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch. Pathol. Lab. Med.<\/i>, 139<\/b>, 876\u2013887 (2015).","DOI":"10.5858\/arpa.2014-0214-RA"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Roser LA, Sakellariou C, Lindstedt M, Neuhaus V, Dehmel S, Sommer C, Raasch M, Flandre T, Roesener S, Hewitt P, Parnham MJ, Sewald K, Schiffmann S. IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept. J. Immunotoxicol.<\/i>, 21<\/b> (sup1), 2332177 (2024).","DOI":"10.1080\/1547691X.2024.2332177"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin. Gastroenterol. Hepatol.<\/i>, 8<\/b>, 463\u2013470 (2010).","DOI":"10.1016\/j.cgh.2010.02.008"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) G\u00f3mez-Lech\u00f3n MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin. Drug Metab. Toxicol.<\/i>, 10<\/b>, 1553\u20131568 (2014).","DOI":"10.1517\/17425255.2014.967680"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Xu Q. Human three-dimensional hepatic models: cell type variety and corresponding applications. Front. Bioeng. Biotechnol.<\/i>, 9<\/b>, 730008 (2021).","DOI":"10.3389\/fbioe.2021.730008"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Ortega-Vallbona R, M\u00e9ndez R, Tolosa L, Escher SE, Castell JV, Gozalbes R, Serrano-Candelas E. Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches. Toxicology<\/i>, 504<\/b>, 153764 (2024).","DOI":"10.1016\/j.tox.2024.153764"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Li T, Qu Y, Chen A, Thakkar S, Li D, Tong W. Beyond QSARs: quantitative knowledge-activity relationships (QKARs) for enhanced drug toxicity prediction. Toxicol. Sci.<\/i>, 208<\/b>, 269\u2013278 (2025).","DOI":"10.1093\/toxsci\/kfaf135"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Calitz C, du Plessis L, Gouws C, Steyn D, Steenekamp J, Muller C, Hamman S. Herbal hepatotoxicity: current status, examples, and challenges. Expert Opin. Drug Metab. Toxicol.<\/i>, 11<\/b>, 1551\u20131565 (2015).","DOI":"10.1517\/17425255.2015.1064110"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Prajapati J, Bhatt N, Rawal R. Hepatoprotective effects of phytochemicals and plant extracts against chemotherapy-induced liver damage in animal models: a systematic review. Arch. Toxicol.<\/i>, 99<\/b>, 887\u2013914 (2025).","DOI":"10.1007\/s00204-024-03928-7"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Lv Y, Hou X, Zhang Q, Li R, Xu L, Chen Y, Tian Y, Sun R, Zhang Z, Xu F. Untargeted metabolomics study of the In vitro<\/i> anti-hepatoma effect of saikosaponin d in combination with NRP-1 knockdown. Molecules<\/i>, 24<\/b>, 1423 (2019).","DOI":"10.3390\/molecules24071423"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Wijesekara T, Luo J, Xu B. Critical review on anti-inflammation effects of saponins and their molecular mechanisms. Phytother. Res.<\/i>, 38<\/b>, 2007\u20132022 (2024).","DOI":"10.1002\/ptr.8164"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Umbaugh DS, Jaeschke H. Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity. Expert Rev. Gastroenterol. Hepatol.<\/i>, 15<\/b>, 363\u2013375 (2021).","DOI":"10.1080\/17474124.2021.1857238"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Przybylak KR, Cronin MTD. In silico<\/i> models for drug-induced liver injury--current status. Expert Opin. Drug Metab. Toxicol.<\/i>, 8<\/b>, 201\u2013217 (2012).","DOI":"10.1517\/17425255.2012.648613"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Ezhilarasan D, Karthikeyan S, Najimi M, Vijayalakshmi P, Bhavani G, Jansi Rani M. Preclinical liver toxicity models: Advantages, limitations and recommendations. Toxicology<\/i>, 511<\/b>, 154020 (2025).","DOI":"10.1016\/j.tox.2024.154020"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Tuschl G, Lauer B, Mueller SO. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin. Drug Metab. Toxicol.<\/i>, 4<\/b>, 855\u2013870 (2008).","DOI":"10.1517\/17425255.4.7.855"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Ge D, An R, Xue L, Qiu M, Zhu Y, Wen G, Shi Y, Ren H, Li W, Wang J. Developing cell-membrane-associated liposomes for liver diseases. ACS Nano<\/i>, 18<\/b>, 29421\u201329438 (2024).","DOI":"10.1021\/acsnano.4c12122"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Lin L, Li H. Analysis of clinical trials of new drugs for liver diseases in China. Drug Des. Devel. Ther.<\/i>, 15<\/b>, 3181\u20133191 (2021).","DOI":"10.2147\/DDDT.S309964"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) M\u00e9ndez-S\u00e1nchez N, Gadano A, Alves de Mattos A, et al.<\/i> Latin american association for the study of the liver practice guidelines. Diagnosis, management, and treatment of hepatitis C. Ann. Hepatol.<\/i>, 9<\/b> (Suppl.), S8\u201326 (2010).","DOI":"10.1016\/S1665-2681(19)31717-X"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Iranshahy M, Rezaee R, Karimi G. Hepatoprotective activity of metformin: a new mission for an old drug? Eur. J. Pharmacol.<\/i>, 850<\/b>, 1\u20137 (2019).","DOI":"10.1016\/j.ejphar.2019.02.004"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/5\/49_b25-00787\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:37:46Z","timestamp":1777693066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/5\/49_b25-00787\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00787","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"b25-00787"}}